To monitor any unexpected risks or basic safety issues. Angiotech recently submitted a safety overview of adverse events from the U.S. Scientific trial to the DSMB, based on having reached the 25 percent enrolment threshold in the U.S. Clinical trial. After that submission, Angiotech received a communication from the DSMB that one of the study groupings had a larger incidence of implant site contamination in comparison with the other study group. Angiotech is blinded to the groups rather than currently aware of if the increased rate of illness is in the patient group that received the graft/Vascular Wrap combination or in the patient group that received the graft alone.Campo advocates avoidance campaigns targeted at freshmen, who are simply beginning to form social ties. And, she says, schools should set guidelines that discourage pledge activities that start early in the freshman season or before the school yr begins.
Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML Astellas Pharma Inc. and Ambit Biosciences Company today announced the initiation of a Phase 2b open-label scientific trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia with FLT3-ITD mutations.